Product Code: MRFR/HC/17313-CR
Market Overview
The Mid-Urethral Sling Market is anticipated to register a healthy CAGR of 5.93% during the forecast period. The rising pervasiveness of urinary incontinence and the rising geriatric populace are driving the market development.
The mid-urethral sling market is supposed to display consistent development during the estimate time frame, driven by the rising commonness of stress urinary incontinence and the interest for insignificantly intrusive techniques. Mechanical headways and enhancements in network materials are additionally expected to drive market development. In any case, concerns with respect to the security of mid-urethral slings might present difficulties to the market's development. Further, geographic development, especially in the Asia-Pacific region, is additionally expected to add to market development.
Urinary incontinence has become more normal as of late due to a few reasons like urinary plot contaminations, neurological issues, stoutness, and pelvic floor issues. The expanded occurrence of pee incontinence has energized market development as additional patients look for extra medicines and supplies to control their side effects. As indicated by the European Commission, north of 56 million people will be impacted by urinary incontinence by 2023.
Market Segmentation
Tension-free Vaginal Tape (TVT) Slings and Transobturator (TOT) Slings are included in the product-based segmentation of the Mid-Urethral Sling Market. The market is separated into two segments based on an indication: Mixed Urinary Incontinence (MUI) and Stress Urinary Incontinence (SUI). The segmentation of the mid-urethral sling market is based on the end user, which might include ambulatory surgical centers, hospitals, and clinics.
Regional Insights
North America mid-urethral sling held the biggest market share in 2022. This is credited to the rising instances of pressure urinary incontinence (SUI) in ladies, high inclination for negligibly obtrusive sling systems, and rising pervasiveness of neurological problems like different sclerosis and Parkinson's illness.
Europe mid-urethral sling market represents the second-biggest market share because of the great frequency of neurological issues in European nations like dementia, stroke, and Alzheimer's sicknesses, expanded rate of pressure urinary incontinence among ladies, and the presence of significant market players in the region.
The Asia-Pacific mid-urethral sling market is anticipated to develop at a fastest development rate during the figure time frame. This is because of a rising number of cesarean conveyances and expanding occurrence of weight and diabetes are a portion of the elements adding to the development of the Asia-Pacific regional market. Moreover, the rising accessibility of clinical service for pressure urinary incontinence (SUI) is projected to draw in unfamiliar interests around here.
Major Players
Key Companies in the Mid-Urethral Sling Market Include Boston Scientific Corporation (US), Coloplast Corp (Denmark), MEDI TECH DEVICES PVT LTD (India), Promedon S.A (Argentina), CALDERA MEDICAL (US), M.I. GmbH (Austria), Johnson & Johnson Services, Inc (US), Betatech Medical (Turkey), UroCure (US), Global Medi Innovations (India), BIcakcIlar (Turkiye), Advin Health Care (India), Lotus Surgicals (India), Biorad Medisys Pvt Ltd (India), and Genev (India).
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 20
2 MARKET INTRODUCTION 22
- 2.1 DEFINITION 22
- 2.2 SCOPE OF THE STUDY 22
- 2.3 RESEARCH OBJECTIVE 22
- 2.4 MARKET STRUCTURE 23
3 RESEARCH METHODOLOGY 24
- 3.1 OVERVIEW 24
- 3.2 DATA FLOW 26
- 3.2.1 Data Mining Process 26
- 3.3 PURCHASED DATABASE: 27
- 3.4 SECONDARY SOURCES: 28
- 3.4.1 Secondary Research Data Flow: 29
- 3.5 PRIMARY RESEARCH: 30
- 3.5.1 Primary Research DATA FLOW: 31
- 3.5.2 Primary Research: Number Of Interviews Conducted 32
- 3.5.3 Primary Research: Regional Coverage 32
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 33
- 3.6.1 Revenue Analysis Approach 33
- 3.7 DATA FORECASTING 33
- 3.7.1 Data Forecasting Technique 34
- 3.8 DATA MODELING 35
- 3.8.1 Microeconomic Factor Analysis: 35
- 3.8.2 Data Modeling: 36
- 3.9 TEAMS AND ANALYST CONTRIBUTION 38
4 MARKET DYNAMICS 40
- 4.1 INTRODUCTION 40
- 4.2 DRIVERS 41
- 4.2.1 Rising Prevalence Of Urinary Incontinence 41
- 4.2.2 Increasing Number Of Geriatric Population 41
- 4.3 RESTRAINTS 42
- 4.3.1 Complications And Risks Due To The Procedure 42
- 4.4 OPPORTUNITY 43
- 4.4.1 Increasing Prevalence Of Chronic Diseases 43
5 MARKET FACTOR ANALYSIS 44
- 5.1 VALUE CHAIN ANALYSIS 44
- 5.1.1 R&D & Designing 45
- 5.1.2 Manufacturing 45
- 5.1.3 Distribution & Sales 45
- 5.1.4 Post-Sales Monitoring 46
- 5.2 PORTER'S FIVE FORCES ANALYSIS 46
- 5.2.1 Threat Of New Entrants 47
- 5.2.2 Bargaining Power Of Suppliers 47
- 5.2.3 Threat Of Substitutes 47
- 5.2.4 Bargaining Power Of Buyers 47
- 5.2.5 Intensity Of Rivalry 48
- 5.3 IMPACT OF COVID-19 ON THE GLOBAL MID-URETHRAL SLING MARKET 48
6 GLOBAL MID-URETHRAL SLING MARKET, BY PRODUCT TYPE 50
- 6.1 OVERVIEW 50
- 6.2 TENSION-FREE VAGINAL TAPE (TVT) SLINGS 52
- 6.3 TRANSOBTURATOR (TOT) SLINGS 52
7 GLOBAL MID-URETHRAL SLING MARKET, BY INDICATION 53
- 7.1 OVERVIEW 53
- 7.2 STRESS URINARY INCONTINENCE (SUI) 55
- 7.2.1 Type I 56
- 7.2.2 Type II 56
- 7.2.3 Type III 57
- 7.3 MIXED URINARY INCONTINENCE (MUI) 57
8 GLOBAL MID-URETHRAL SLING MARKET, BY END USER 58
- 8.1 OVERVIEW 58
- 8.2 HOSPITALS AND CLINICS 60
- 8.3 AMBULATORY SURGICAL CENTERS 61
- 8.4 OTHERS 61
9 GLOBAL MID-URETHRAL SLING MARKET, BY REGION 62
- 9.1 GLOBAL 62
- 9.2 NORTH AMERICA 64
- 9.2.1 US 67
- 9.2.2 CANADA 68
- 9.3 EUROPE 70
- 9.3.1 Germany 73
- 9.3.2 France 74
- 9.3.3 Uk 75
- 9.3.4 Italy 77
- 9.3.5 Spain 78
- 9.3.6 Rest Of Europe 79
- 9.4 ASIA-PACIFIC 81
- 9.4.1 China 84
- 9.4.2 India 85
- 9.4.3 Japan 86
- 9.4.4 South Korea 88
- 9.4.5 Rest Of Asia-Pacific 89
- 9.5 REST OF THE WORLD 91
- 9.5.1 Middle East & Africa 94
- 9.5.2 South America 95
10 COMPETITIVE LANDSCAPE 98
- 10.1 INTRODUCTION 98
- 10.2 MARKET SHARE ANALYSIS, 2022 98
- 10.3 COMPETITOR DASHBOARD 99
- 10.4 MARKET SHARE, REVENUE, UNITE SALES AND GROSS MARGIN OF MIDURETHREAL SLINGS 100
- 10.5 PUBLIC PLAYERS STOCK SUMMARY 100
- 10.6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 100
- 10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 101
- 10.7.1 PRODUCT LAUNCH/PRODUCT APPROVAL 101
- 10.7.2 PARTNERSHIP/INVESTMENT/EXPANSION 102
11 COMPANY PROFILES 103
- 11.1 BOSTON SCIENTIFIC CORPORATION 103
- 11.1.1 COMPANY OVERVIEW 103
- 11.1.2 FINANCIAL OVERVIEW 104
- 11.1.3 PRODUCTS OFFERED 104
- 11.1.4 KEY DEVELOPMENTS 105
- 11.1.5 SWOT ANALYSIS 105
- 11.1.6 KEY STRATEGIES 105
- 11.2 COLOPLAST CORP 106
- 11.2.1 COMPANY OVERVIEW 106
- 11.2.2 FINANCIAL OVERVIEW 107
- 11.2.3 PRODUCTS OFFERED 107
- 11.2.4 KEY DEVELOPMENTS 107
- 11.2.5 SWOT ANALYSIS 108
- 11.2.6 KEY STRATEGIES 108
- 11.3 MEDI TECH DEVICES PVT LTD 109
- 11.3.1 COMPANY OVERVIEW 109
- 11.3.2 FINANCIAL OVERVIEW 109
- 11.3.3 PRODUCTS OFFERED 110
- 11.3.4 KEY DEVELOPMENTS 110
- 11.3.5 KEY STRATEGIES 110
- 11.4 PROMEDON S.A. 111
- 11.4.1 COMPANY OVERVIEW 111
- 11.4.2 FINANCIAL OVERVIEW 111
- 11.4.3 PRODUCTS OFFERED 112
- 11.4.4 KEY DEVELOPMENTS 112
- 11.4.5 KEY STRATEGIES 112
- 11.5 CALDERA MEDICAL 113
- 11.5.1 COMPANY OVERVIEW 113
- 11.5.2 FINANCIAL OVERVIEW 113
- 11.5.3 PRODUCTS OFFERED 114
- 11.5.4 KEY DEVELOPMENTS 114
- 11.5.5 SWOT ANALYSIS 115
- 11.5.6 KEY STRATEGIES 115
- 11.6 A.M.I. GMBH 116
- 11.6.1 COMPANY OVERVIEW 116
- 11.6.2 FINANCIAL OVERVIEW 116
- 11.6.3 DISEASE TYPES OFFERed 116
- 11.6.4 KEY DEVELOPMENTS 117
- 11.6.5 SWOT ANALYSIS 117
- 11.6.6 Key Strategy 117
- 11.7 JOHNSON & JOHNSON SERVICES, INC 118
- 11.7.1 COMPANY OVERVIEW 118
- 11.7.2 FINANCIAL OVERVIEW 119
- 11.7.3 Products OFFERed 119
- 11.7.4 KEY DEVELOPMENTS 120
- 11.7.5 SWOT Analysis 120
- 11.7.6 KEY STRATEGIES 120
- 11.8 BETATECH MEDICAL 121
- 11.8.1 COMPANY OVERVIEW 121
- 11.8.2 FINANCIAL OVERVIEW 121
- 11.8.3 Products OFFERed 122
- 11.8.4 KEY DEVELOPMENTS 122
- 11.8.5 Key Strategy 122
- 11.9 UROCURE 123
- 11.9.1 COMPANY OVERVIEW 123
- 11.9.2 FINANCIAL OVERVIEW 124
- 11.9.3 DISEASE TYPES OFFERed 124
- 11.9.4 KEY DEVELOPMENTS 124
- 11.9.5 KEY STRATEGIES 124
- 11.10 GLOBAL MEDI INNOVATIONS 125
- 11.10.1 COMPANY OVERVIEW 125
- 11.10.2 FINANCIAL OVERVIEW 125
- 11.10.3 DISEASE TYPES OFFERed 126
- 11.10.4 KEY DEVELOPMENTS 126
- 11.10.5 KEY STRATEGIES 126
- 11.11 BICAKCILAR 126
- 11.11.1 COMPANY OVERVIEW 126
- 11.11.2 FINANCIAL OVERVIEW 127
- 11.11.3 DISEASE TYPES OFFERed 127
- 11.11.4 KEY DEVELOPMENTS 127
- 11.11.5 SWOT ANALYSIS 127
- 11.11.6 Key Strategy 128
- 11.12 ADVIN HEALTH CARE 128
- 11.12.1 COMPANY OVERVIEW 128
- 11.12.2 FINANCIAL OVERVIEW 128
- 11.12.3 Products OFFERed 128
- 11.12.4 KEY DEVELOPMENTS 129
- 11.12.5 SWOT Analysis 129
- 11.12.6 KEY STRATEGIES 129
- 11.13 LOTUS SURGICALS 130
- 11.13.1 COMPANY OVERVIEW 130
- 11.13.2 FINANCIAL OVERVIEW 130
- 11.13.3 Products OFFERed 130
- 11.13.4 KEY DEVELOPMENTS 131
- 11.13.5 SWOT Analysis 131
- 11.13.6 Key Strategy 131
- 11.14 BIORAD MEDISYS PVT LTD 132
- 11.14.1 COMPANY OVERVIEW 132
- 11.14.2 FINANCIAL OVERVIEW 133
- 11.14.3 DISEASE TYPES OFFERed 133
- 11.14.4 KEY DEVELOPMENTS 133
- 11.14.5 SWOT Analysis 133
- 11.14.6 KEY STRATEGIES 134
- 11.15 GENEV 134
- 11.15.1 COMPANY OVERVIEW 134
- 11.15.2 FINANCIAL OVERVIEW 134
- 11.15.3 DISEASE TYPES OFFERed 135
- 11.15.4 KEY DEVELOPMENTS 135
- 11.15.5 SWOT Analysis 135
- 11.15.6 KEY STRATEGIES 135
12 DATA CITATIONS 136